Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.
A novel triple-targeted therapy shows feasibility and tolerability in people with advanced HER2-positive tumors resistant to standard drugs.
This PubMed record reports that these findings indicate that SAR443216 treatment is feasible and well tolerated in participants with R/R HER2+solid tumors. It provides randomized controlled trial evidence relevant to Novel therapeutics.
What the study was
- Study design
- Randomized controlled trial
- Category
- Other
- Maturity
- Exploratory
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
Conservative rapid triage based on the PubMed abstract and citation metadata; randomized controlled trial with other relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.